Doxorubicin + Cyclophosphamide + Taxane + Letrozole + Abemaciclib + LHRH Analogue
Phase 2Active 1 views this week 0 watching💤 Quiet
Interest: 39/100
39
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Early Breast Cancer
Conditions
Early Breast Cancer
Trial Timeline
Oct 2, 2020 → Feb 28, 2033
NCT ID
NCT04293393About Doxorubicin + Cyclophosphamide + Taxane + Letrozole + Abemaciclib + LHRH Analogue
Doxorubicin + Cyclophosphamide + Taxane + Letrozole + Abemaciclib + LHRH Analogue is a phase 2 stage product being developed by Eli Lilly for Early Breast Cancer. The current trial status is active. This product is registered under clinical trial identifier NCT04293393. Target conditions include Early Breast Cancer.
What happened to similar drugs?
2 of 20 similar drugs in Early Breast Cancer were approved
Approved (2) Terminated (2) Active (17)
❌PERT-IJS plus trastuzumab, carboplatin and docetaxel + Perjeta plus trastuzumab, carboplatin and docetaxelBioconPhase 3
🔄SHR-A1811 for Injection + Docetaxel injection + Trastuzumab Injection + Carboplatin for Injection + Pertuzumab InjectionJiangsu Hengrui MedicinePhase 3
🔄SHR7280；Ganirelix Acetate Injection simulant + SHR7280 simulant； Ganirelix Acetate InjectionJiangsu Hengrui MedicinePhase 3
Hype Score Breakdown
Clinical
12
Activity
12
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04293393 | Phase 2 | Active |
Competing Products
20 competing products in Early Breast Cancer